Repatha (Evolocumab) for Adolescents Ages 12 to 17: Caregiver Administration Guide

Why Your Teen Daughter May Need Repatha

Familial hypercholesterolemia (FH) is one of the most common inherited metabolic conditions, affecting roughly 1 in 250 people for the heterozygous form. Girls with FH carry the same cardiovascular risk as boys, yet a 2022 registry analysis found that adolescent females with FH are diagnosed and treated later than their male peers, a gap that delays the window for atherosclerosis prevention during a critical decade.

Statins remain first-line therapy for adolescent FH, but a meaningful subset of girls cannot reach guideline LDL targets on statins alone, or they experience statin-related muscle symptoms that limit dose escalation. Repatha (evolocumab) fills that gap as a fully human monoclonal antibody that inhibits PCSK9, the protein that degrades LDL receptors on liver cells. By blocking PCSK9, evolocumab allows more LDL receptors to recycle to the cell surface and pull cholesterol out of the bloodstream.

FDA approval for the 12-to-17 age group covers two indications: heterozygous FH (HeFH) and homozygous FH (HoFH). The HAUSER-RCT trial, which enrolled adolescents including girls, demonstrated that evolocumab reduced LDL-C by a mean of 38.3% versus placebo at 24 weeks in HeFH patients ages 10 to 17.

Why Caregiver Administration Matters for This Age Group

Many teens need a caregiver present for injections, at least initially. Needle anxiety is common, fine motor coordination varies, and the emotional weight of a chronic injectable therapy can make a trusted adult's involvement meaningful beyond the mechanical task. This guide is written for you, the caregiver, so you can administer Repatha correctly and help your daughter build confidence over time.

How Female Physiology Shapes LDL and Repatha Response

Estrogen and progesterone influence lipid metabolism in ways that matter when you are monitoring your daughter's cholesterol levels.

The Menstrual Cycle and Cholesterol Variability

LDL-cholesterol is not flat across the month. Estrogen upregulates hepatic LDL receptors, so LDL tends to be lowest during the follicular phase (days 2 through 14 in a typical cycle) and somewhat higher in the luteal phase, when progesterone dominates. Research published in Metabolism has shown intra-cycle LDL variation of 5 to 10% in healthy women, which can obscure or exaggerate apparent drug response if labs are drawn on different cycle days.

For the most reproducible LDL monitoring in your daughter, schedule repeat lipid panels during days 2 through 5 of her menstrual cycle when feasible. This is not a requirement in current FH guidelines, but it is a practical step that reduces measurement noise.

Hormonal Contraception and Lipids

If your daughter is on combined oral contraceptives or a progestogenic hormonal method, her baseline lipid picture may differ from a non-medicated peer. Progestins with higher androgenic activity (older levonorgestrel formulations) can raise LDL and lower HDL modestly, while estrogen-containing pills generally lower LDL. Her cardiologist or lipid specialist should factor this in when setting her LDL target.

Dosing: What the Prescriber Orders and Why

The prescribing clinician selects from three approved regimens for adolescents with HeFH or HoFH:

| Indication | Dose | Frequency | Device | |---|---|---|---| | HeFH | 140 mg | Every 2 weeks | SureClick autoinjector or prefilled syringe | | HeFH | 420 mg | Once monthly | Pushtronex on-body infusor OR three 140 mg injections within 30 minutes | | HoFH | 420 mg | Every 2 weeks | SureClick (three injections) or Pushtronex |

Body weight does not alter the dose in this age group based on current labeling. Girls with HoFH who are also on LDL apheresis should keep their scheduled apheresis sessions; Repatha is used adjunctively, not as a replacement.

Step-by-Step Caregiver Injection Guide: SureClick Autoinjector (140 mg)

The SureClick is the device most adolescent patients and caregivers start with. Each autoinjector contains one 140 mg/mL prefilled dose. Follow these steps exactly.

Step 1: Gather Supplies and Check the Medication

Remove the autoinjector from the refrigerator at least 30 minutes before injection to let it reach room temperature. Cold medication stings more on injection. Do not warm it with a microwave, hot water, or direct sunlight.

Check the expiration date on the carton. Hold the device up to light and look through the viewing window. The liquid should be clear to slightly opalescent and colorless to pale yellow. Do not inject if you see visible particles, cloudiness, or discoloration. Call the pharmacy for a replacement.

Step 2: Choose and Prepare the Injection Site

Acceptable sites are:

• The abdomen, at least 2 inches from the navel
• The front or outer thigh
• The upper outer arm (if someone else is giving the injection, which is typical for caregiver administration)

Wipe the chosen site with an alcohol swab and let it air-dry for 10 seconds. Do not blow on it or fan it. Avoid areas that are bruised, tender, red, or scarred. Each injection should be at least 1 inch from the previous site.

Step 3: Inject

Pull the orange cap straight off. Do not twist. Place the device flat against the skin at a 90-degree angle and press firmly. You will hear a first click that signals the injection has started. Keep pressing until you hear a second click and see the orange indicator fill the window completely, confirming the full dose was delivered. Lift the device straight off.

Your daughter may feel a brief sting or pressure. This is normal. Hold light pressure over the site with a cotton ball for 10 seconds; do not rub.

Step 4: Dispose Safely

Place the used autoinjector immediately in an FDA-cleared sharps container. Do not recap, bend, or cut the needle. When the container is three-quarters full, seal it and dispose of it per your local guidelines. Many pharmacies accept used sharps containers.

Administering the 420 mg Monthly Dose: Three-Injection Protocol

If your daughter's prescriber chose the 420 mg once-monthly regimen and you are using SureClick devices rather than the Pushtronex infusor, you will inject three 140 mg autoinjectors consecutively within 30 minutes.

Use three different sites or rotate within one site area (for example, left abdomen upper quadrant, left abdomen lower quadrant, right abdomen). Each injection follows the same four-step protocol above. Keep a timer running to ensure all three are completed within 30 minutes of the first.

Some caregivers find it easier to prepare all three devices on a clean surface before starting, so there is no scrambling between injections.

The Pushtronex On-Body Infusor: What Caregivers Need to Know

The Pushtronex is a wearable, one-time-use device that delivers 420 mg over 9 minutes through a small subcutaneous cannula attached to the abdomen. Some families prefer it because it eliminates three consecutive needle sticks. However, it requires more setup steps than the SureClick.

The carton contains one Pushtronex unit pre-filled at the factory. Key points:

• Attach only to the abdomen, not the arm or thigh.
• Remove from refrigerator 45 minutes before use (longer warm-up than SureClick).
• Peel the liner, place on skin, and press the button. The device beeps and a yellow indicator fills as medication is delivered.
• Do not remove it during infusion. If the device falls off mid-dose, call the prescribing office before attempting a replacement dose.

Storage, Travel, and Practical Logistics

Repatha must be stored refrigerated between 2°C and 8°C (36°F and 46°F) in the original carton to protect it from light. It may be kept at room temperature at or below 25°C (77°F) for up to 30 days if kept in the original carton. Once it has been at room temperature for 30 days, it must be used or discarded; do not return it to the refrigerator.

For school trips, sports travel, and vacations, use a soft-sided insulated cooler with an ice pack wrapped in a cloth (not in direct contact with the device, which could freeze it). Freezing degrades the antibody; frozen product must be discarded.

If you use a specialty pharmacy for home delivery, confirm cold-chain handling before accepting the shipment. Check the temperature indicator on the package if one is included.

What to Do If a Dose Is Missed

If your daughter misses a scheduled injection:

• Every-2-week regimen: Inject as soon as you remember, then resume the original schedule if the missed dose is administered more than 7 days before the next scheduled date. If fewer than 7 days remain until the next dose, skip the missed dose and resume the regular schedule.
• Once-monthly regimen: Inject as soon as possible, then schedule the next injection one month from that date, not from the original missed date.

Do not double up on doses. Missing one injection is not a clinical emergency for most adolescents with HeFH, but call the prescriber if you miss two consecutive doses so they can reassess LDL control.

Pregnancy, Contraception, and Lactation: A Required Conversation for Teen Girls

Repatha is contraindicated during pregnancy. This is not a theoretical risk: PCSK9 is expressed in fetal tissues and may have developmental roles not yet fully characterized. The current FDA label states there are no adequate human data on use during pregnancy to establish drug-associated risk.

Animal studies using doses several times the human dose showed no overt fetal harm, but animal data do not reliably predict human fetal risk for monoclonal antibodies, which can cross the placenta via the FcRn receptor beginning in the second trimester. IgG1 antibodies like evolocumab are actively transported across the placenta, meaning fetal exposure increases as pregnancy advances.

What This Means for Your Daughter Right Now

Any adolescent girl who is sexually active or considering becoming sexually active while on Repatha must use reliable contraception. The prescribing clinician should discuss contraceptive options at the time Repatha is started. Acceptable options include:

• Combined oral contraceptives (noting their modest effect on her lipid panel, as above)
• Progestin-only pills
• Long-acting reversible contraception (IUD or implant)
• Barrier methods used consistently

If your daughter becomes pregnant while taking Repatha, she should stop the medication immediately and contact her care team. Amgen maintains a pregnancy exposure registry at 1-800-77-AMGEN; enrollment is encouraged so that any pregnancy outcomes can be tracked to add to the limited human safety dataset.

Lactation

There is no published human data on evolocumab transfer into breast milk. Because evolocumab is a large-molecule IgG1 antibody, it is unlikely to be absorbed in significant amounts by a nursing infant even if present in milk; however, this has not been studied directly. The FDA label advises that the decision to breastfeed while on evolocumab should weigh the developmental and health benefits of breastfeeding against the mother's need for the medication. For a 12-to-17-year-old, this scenario is uncommon, but postpartum teens deserve the same evidence-based conversation.

Side Effects: What Adolescent Girls Should Know

The overall safety profile of evolocumab in adolescents generally mirrors that seen in adults. The HAUSER-RCT trial reported that the most common adverse events were nasopharyngitis, headache, and injection-site reactions, occurring at similar rates in the evolocumab and placebo arms.

Injection-Site Reactions

Redness, bruising, swelling, or pain at the injection site occurs in a small percentage of patients. Rotating sites consistently reduces this risk. If a reaction persists beyond 48 hours or involves significant swelling, contact the prescriber.

Muscle Symptoms

Myalgia is far more commonly attributed to statins than to PCSK9 inhibitors. In adolescent trials, muscle-related adverse events with evolocumab were not significantly higher than placebo. Still, if your daughter reports new or worsening muscle pain after Repatha is added, document the timing and report it.

Neurocognitive Concerns: What the Evidence Actually Shows

Early post-marketing surveillance of PCSK9 inhibitors in adults raised a question about memory or cognitive symptoms. The EBBINGHAUS trial, a dedicated cognitive sub-study of the FOURIER cardiovascular outcomes trial, found no significant difference in neurocognitive function between evolocumab and placebo in over 1,200 adults. No comparable prospective cognitive study has been conducted in adolescents specifically, which is a genuine evidence gap worth acknowledging.

Allergic Reactions

Serious hypersensitivity reactions are rare. Signs to watch for include hives, facial swelling, difficulty breathing, or a feeling of tightness in the throat. These require emergency care immediately.

Who This Is Right for, and Who Should Pause

Girls Who Are Good Candidates

• Diagnosed HeFH or HoFH confirmed by genetic testing or clinical criteria
• Aged 12 through 17 at the time of initiation
• Already on maximally tolerated statin therapy with or without ezetimibe, and LDL still above guideline targets (typically <100 mg/dL for HeFH or <70 mg/dL for high-risk HeFH per ACC/AHA guidance)
• Not pregnant, not planning pregnancy in the near term, and using or willing to use reliable contraception if sexually active

Girls Who Should Wait or Reconsider

• Actively trying to conceive or currently pregnant (stop Repatha and discuss alternatives)
• Known serious hypersensitivity to evolocumab or any excipient
• LDL targets already met on statin plus ezetimibe (adding Repatha would not be cost-justified)
• Girls with LDL elevation from secondary causes (hypothyroidism, nephrotic syndrome) that have not yet been treated, since correcting the underlying cause may normalize LDL without additional therapy

A Note on PCOS and Metabolic Context

Adolescent girls with polycystic ovary syndrome (PCOS) have a higher prevalence of dyslipidemia and insulin resistance, which can drive LDL and non-HDL elevation independently of FH. A 2020 meta-analysis in Fertility and Sterility confirmed elevated cardiovascular risk markers in adolescents with PCOS. If your daughter has both PCOS and FH, her lipid management plan should address insulin resistance (often with lifestyle and metformin) alongside PCSK9 inhibition so that each driver of dyslipidemia is targeted.

Monitoring Schedule for Adolescent Girls on Repatha

Once Repatha is started, your daughter's care team will check LDL-C approximately 4 to 12 weeks after initiation to confirm response, then every 3 to 12 months depending on her clinical stability. Liver enzymes and CK are not routinely required on Repatha in the absence of symptoms, unlike higher-intensity statin monitoring.

Ask for the fasting lipid panel to be scheduled consistently in the cycle-day window described earlier (days 2 through 5) if her cycles are regular. Record the cycle day on lab requisitions. This produces cleaner longitudinal data and avoids the clinical noise of luteal-phase LDL variability.

Weight, height, and BMI should be tracked at each visit because body composition changes during adolescence can affect cardiovascular risk stratification even when LDL targets are met.

Helping Your Teen Daughter Adjust to an Injectable Therapy

Chronic injectable therapy at 12 to 17 years old carries a psychological load that goes beyond the needle itself. Research on adolescent adherence to injectable therapies shows that caregiver involvement in the first 3 to 6 months predicts better long-term self-administration rates.

Practical strategies that families report as useful:

• Practice the injection sequence with the device cap on before the first real injection.
• Let your daughter choose the injection site when she is ready, giving her some control.
• Use a topical numbing cream (EMLA or LMX4) applied 45 minutes before the injection if needle anxiety is significant. Ask the prescriber to note this in the care plan.
• Keep a simple injection log (date, site, any reactions) in a phone note or calendar. This doubles as an adherence record for clinic visits.
• Connect with FH advocacy communities such as the FH Foundation, where teen-specific peer support is available.

Adolescent girls are more likely than boys to report injection anxiety in self-report surveys, though they also show comparable rates of successful self-administration once trained. Your presence as a calm, prepared caregiver is the single biggest predictor of a smooth early experience.